Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478372 | 0.81 | NAMPT (0.43) | HTR6NAMPT | |
| SCHEMBL30765522 | 0.79 | FAAH (0.40) | HTR6MAPTCYP2C9 | |
| Trifluoroacetic Acid SCHEMBL23452232 | 0.76 | HTR6 (0.42) | ACHEFEN1HTR6MAPTPARP1 | |
| SCHEMBL23491339 | 0.75 | L3MBTL1 (0.41) | MAPT | |
| SCHEMBL23478373 | 0.74 | HTR6 (0.51) | ACHEFEN1HTR6MAPTPARP1 | |
| SCHEMBL23473995 | 0.69 | ACHE (0.51) | ACHEFEN1HTR6MAPTPARP1 | |
| SCHEMBL23452339 | 0.69 | F2 (0.48) | NAMPTCYP2C9 | |
| SCHEMBL27140579 | 0.69 | SMN1; SMN2 (0.45) | MAPTHSD17B10 | |
| SCHEMBL30997382 | 0.68 | NAMPT (0.54) | NAMPTHSD17B10NPSR1CYP2C9 | |
| SCHEMBL30765895 | 0.66 | NAMPT (0.43) | HTR6MAPTPARP1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ACHE 2723/4885FEN1 2348/4885HTR6 4242/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ACHE 2723/4885FEN1 2348/4885HTR6 4242/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ACHE 2723/4885FEN1 2348/4885HTR6 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.